Zoetis Inc. and Amneal Pharmaceuticals, Inc.: A Detailed Gross Profit Analysis

A Comparative Analysis of Gross Profit: Zoetis Inc. vs. Amneal Pharmaceuticals, Inc.

In the ever-evolving pharmaceutical industry, understanding financial performance is crucial. This analysis delves into the gross profit trends of Zoetis Inc. and Amneal Pharmaceuticals, Inc. from 2014 to 2023. Over this period, Zoetis Inc. consistently outperformed Amneal Pharmaceuticals, with its gross profit growing by approximately 90%, reaching its peak in 2023. In contrast, Amneal Pharmaceuticals experienced a more modest growth of around 82% during the same timeframe.

Key Insights

• Zoetis Inc.: Demonstrated a robust upward trajectory, with gross profits increasing from 3.1 billion in 2014 to 5.8 billion in 2023.
• Amneal Pharmaceuticals, Inc.: Despite fluctuations, it managed to increase its gross profit from 450 million in 2014 to 820 million in 2023.

This data underscores the dynamic nature of the pharmaceutical sector, highlighting Zoetis Inc.'s strong market position and Amneal's resilience.